Trial ID or NCT#

NCT02492711

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.

Official Title

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Mark Pegram
Mark Pegram
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor

Contact us to find out if this trial is right for you.

CONTACT

Annabel Castaneda
(650) 728-7977